Cover Image
市場調查報告書

PharmaPoint:重度憂鬱症 - 日本的醫藥品的預測與市場分析

PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 305472
出版日期 內容資訊 英文 136 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:重度憂鬱症 - 日本的醫藥品的預測與市場分析 PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023
出版日期: 2014年05月30日 內容資訊: 英文 136 Pages
簡介

重度憂鬱症是全球最常見的精神疾病之一。該市場的競爭激烈,有超過30種產品治療藥正在上市。在主要產品的專利到期、最終階段的開發平台產品投入市場的當下,市場正在大大變動中。日本預測有Brintellix及7種位於最終階段的開發中產品即將上市。其他再加上Cymbalta、Lexapro的銷售額預測將達到1億6200萬美元。

本報告提供日本重度憂鬱症的治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等彙整資料,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 分類
  • 症狀及亞型
  • 預後
  • QOL

第4章 疾病的管理

  • 症狀和治療概要
  • 日本

第5章 競爭評估

  • 概要
  • 產品簡介:領導品牌,選擇性血清素再吸收抑制劑
  • 產品簡介:領導品牌,血清素-去甲腎上腺素再吸收抑制劑
  • 產品簡介:領導品牌,其他抗憂鬱症藥
  • 產品簡介:領導品牌,抗精神藥
  • 其他的治療藥物級

第6章 機會及未滿足需求

  • 概要
  • 更有效的藥物療法
  • 更良好的副作用簡介
  • 效果快速的抗憂鬱效果
  • 個人化醫療的方法

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
  • 其他開發中的藥物

第8章 市場預測

  • 日本

第9章 附錄

圖表

目錄
Product Code: GDHC244CFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

The anticipated growth of the depression market in Japan is due to the expected launch of Brintellix and the potential introduction of seven late-stage pipeline products into the market during the forecast period. GlobalData anticipates Elli Lilly's Cymbalta and Lundbeck/Forest (Actavis)/Mitsubishi Tanabe Pharma/Mochida's Lexapro to be the top-selling products by the end of the forecast period in Japan, generating combined sales of approximately $162.2m.

Scope

  • Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Major depressive disorder market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in Japan.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms and Subtypes of Major Depressive Disorder
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. Japan

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles: Major Brands, Selective Serotonin Reuptake Inhibitors
    • 5.2.1. Lexapro (Escitalopram)
    • 5.2.2. Other Selective Serotonin Reuptake Inhibitors
  • 5.3. Product Profiles: Major Brands, Serotonin-Norepinephrine Reuptake Inhibitors
    • 5.3.1. Cymbalta (Duloxetine)
  • 5.4. Product Profiles: Major Brands, Other Antidepressants
    • 5.4.1. Noradrenaline and Specific Serotonergic Antidepressants
    • 5.4.2. Tricyclic Antidepressants
    • 5.4.3. Brintellix (Vortioxetine)
  • 5.5. Product Profiles: Major Brands, Antipsychotics
    • 5.5.1. Abilify (Aripiprazole)
    • 5.5.2. Seroquel XR (Quetiapine)
  • 5.6. Other Therapeutic Classes

6. Unmet Needs and Opportunities

  • 6.1. Overview
  • 6.2. More Effective Pharmacotherapies
    • 6.2.1. Unmet Needs
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunities
  • 6.3. More Favorable Side Effect Profiles
    • 6.3.1. Unmet Needs
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunities
  • 6.4. Rapid Onset of Antidepressant Effects
    • 6.4.1. Unmet Needs
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunities
  • 6.5. Personalized Treatment Approach
    • 6.5.1. Unmet Needs
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunities

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Brexpiprazole (OPC-34712)
    • 7.2.2. Cariprazine (RGH-188)
    • 7.2.3. ALKS-5461
    • 7.2.4. Amitifadine (EB-1010)
    • 7.2.5. GLYX-13
    • 7.2.6. Tedatioxetine (Lu AA24530)
    • 7.2.7. ETS6103
  • 7.3. Other Drugs in Development

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers - Global Issues
    • 8.1.4. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed MDD Patients
    • 9.4.2. Percent of Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Analyst
    • 9.6.2. Therapy Area Directors
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 4: Treatment Guidelines for Major Depressive Disorder
  • Table 5: Most Prescribed Drugs for MDD by Class in Japan, 2013
  • Table 6: Country Profile - Japan
  • Table 7: Leading Treatments for MDD, 2013
  • Table 8: Product Profile - Lexapro
  • Table 9: Safety of Lexapro - Five Most Frequently Reported Adverse Events
  • Table 10: Lexapro SWOT Analysis, 2014
  • Table 11: Relative Frequency of Common Adverse Effects for Different SSRIs
  • Table 12: Product Profile - Cymbalta
  • Table 13: Cymbalta SWOT Analysis, 2023
  • Table 14: Product Profile - Mirtazapine
  • Table 15: Safety of Mirtazapine - Four Most Frequently Reported Adverse Events
  • Table 16: Mirtazapine SWOT Analysis, 2014
  • Table 17: TCAs SWOT Analysis, 2014
  • Table 18: Product Profile - Brintellix
  • Table 19: Efficacy of Brintellix in Six-Week to Eight-Week Clinical Trials
  • Table 20: Safety of Brintellix - Five Most Frequently Reported Adverse Events
  • Table 21: Brintellix SWOT Analysis, 2014
  • Table 22: Product Profile - Abilify
  • Table 23: Safety of Abilify - Five Most Frequently Reported Adverse Events
  • Table 24: Abilify SWOT Analysis, 2014
  • Table 25: Product Profile - Seroquel XR
  • Table 26: Efficacy of Seroquel XR as an Adjunctive Therapy to Antidepressants
  • Table 27: Safety of Seroquel XR- Five Most Frequently Reported Adverse Events
  • Table 28: Seroquel XR SWOT Analysis, 2014
  • Table 29: Summary of Minor Therapeutic Classes in MDD, 2013
  • Table 30: Unmet Needs and Opportunities in MDD
  • Table 31: Comparison of Therapeutic Classes in Development for MDD, 2013
  • Table 32: Product Profile - Brexpiprazole
  • Table 33: Safety of Brexpiprazole - Most Frequently Reported Adverse Events
  • Table 34: Brexpiprazole SWOT Analysis, 2014
  • Table 35: Product Profile - Cariprazine
  • Table 36: Cariprazine SWOT Analysis, 2014
  • Table 37: Product Profile - ALKS-5461
  • Table 38: ALKS-5461 SWOT Analysis, 2014
  • Table 39: Product Profile - Amitifadine
  • Table 40: Amitifadine SWOT Analysis, 2014
  • Table 41: Product Profile - GLYX-13
  • Table 42: GLYX-13 SWOT Analysis, 2014
  • Table 43: Product Profile - Tedatioxetine
  • Table 44: Tedatioxetine SWOT Analysis, 2014
  • Table 45: Product Profile - ETS6103
  • Table 46: ETS6103 SWOT Analysis, 2014
  • Table 47: Drugs in Development for MDD, 2014
  • Table 48: Sales Forecasts ($m) for MDD in Japan, 2013-2023
  • Table 49: Key Events Impacting Sales for MDD in Japan, 2013-2023
  • Table 50: MDD Market - Drivers and Barriers, 2013-2023
  • Table 51: MDD Market in Japan - Drivers and Barriers, 2013-2013
  • Table 52: Key Launch Dates
  • Table 53: Key Patent Expiries
  • Table 54: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Disease Management Model for Major Depressive Disorder
  • Figure 3: Major Depressive Disorder Treatment Algorithm
  • Figure 4: MDD - Phase IIb-III Pipeline, 2014
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2013-2023
  • Figure 6: Clinical and Commercial Positioning of Brexpiprazole
  • Figure 7: Clinical and Commercial Positioning of Cariprazine
  • Figure 8: Clinical and Commercial Positioning of ALKS-5461
  • Figure 9: Clinical and Commercial Positioning of Amitifadine
  • Figure 10: Clinical and Commercial Positioning of GLYX-13
  • Figure 11: Clinical and Commercial Positioning of Tedatioxetine
  • Figure 12: Clinical and Commercial Positioning of ETS6103
  • Figure 13: Sales for MDD in Japan by Drug Class, 2013-2023
Back to Top